Attenuated T-lymphocyte response to HIV therapy in individuals receiving HMG-CoA reductase inhibitors

Shanil Narayan, Nanci Hawley, Pierre Giguère, Andrew David Badley

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Purpose: The protease inhibitor class of antiretroviral agents is associated with the unwanted side effect of hypertriglyceridemia, which is usually treated with either HMG-CoA reductase inhibitors (statins) or fibrates. However, since statin therapy is intrinsically immunomodulatory, we questioned whether the T-cell response of patients who received PI-based therapy plus statin differed from the response of patients on PI therapy alone or on PI therapy with a fibrate. Method: Retrospective cohort study. Results: Thirty-five patients who had received ritonavir/saquinavir (R/S)-based antiretroviral therapy for 5 or more years were evaluated and stratified into four treatment groups: patients on R/S alone (n = 9), patients on R/S and stavudine/lamivudine (d4T/3TC) (n = 10), patients on R/S with or without d4T/3TC and statin (n = 11), or patients on R/S with or without d4T/3TC and fibrate (n = 5). All patients had suppressed levels of viral replication at all time points. T-cell responses were similar in all four groups before they were exposed to lipid-lowering agents. After the addition of lipid-lowering agents, absolute CD4 T-cell responses were lower in the statin group than in all other groups (p < .05), when measured after 6, 12, and 18 months of treatment. Conclusion: These data suggest that T-cell responses are influenced by the choice of anti-lipid agent and suggest that a prospective comparison is needed to determine the clinical relevance of these findings.

Original languageEnglish (US)
Pages (from-to)164-169
Number of pages6
JournalHIV Clinical Trials
Volume4
Issue number3
DOIs
StatePublished - May 2003

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
HIV
T-Lymphocytes
Lamivudine
Fibric Acids
Therapeutics
Lipids
Saquinavir
Anti-Retroviral Agents
Stavudine
Ritonavir
Hypertriglyceridemia
Protease Inhibitors
Cohort Studies
Retrospective Studies

Keywords

  • CD4 T-cell response
  • Fibrates
  • HMG-CoA reductase inhibitors
  • Hyperlipidemia

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Attenuated T-lymphocyte response to HIV therapy in individuals receiving HMG-CoA reductase inhibitors. / Narayan, Shanil; Hawley, Nanci; Giguère, Pierre; Badley, Andrew David.

In: HIV Clinical Trials, Vol. 4, No. 3, 05.2003, p. 164-169.

Research output: Contribution to journalArticle

Narayan, Shanil ; Hawley, Nanci ; Giguère, Pierre ; Badley, Andrew David. / Attenuated T-lymphocyte response to HIV therapy in individuals receiving HMG-CoA reductase inhibitors. In: HIV Clinical Trials. 2003 ; Vol. 4, No. 3. pp. 164-169.
@article{96794b31304749409e5e1b1764aa7e77,
title = "Attenuated T-lymphocyte response to HIV therapy in individuals receiving HMG-CoA reductase inhibitors",
abstract = "Purpose: The protease inhibitor class of antiretroviral agents is associated with the unwanted side effect of hypertriglyceridemia, which is usually treated with either HMG-CoA reductase inhibitors (statins) or fibrates. However, since statin therapy is intrinsically immunomodulatory, we questioned whether the T-cell response of patients who received PI-based therapy plus statin differed from the response of patients on PI therapy alone or on PI therapy with a fibrate. Method: Retrospective cohort study. Results: Thirty-five patients who had received ritonavir/saquinavir (R/S)-based antiretroviral therapy for 5 or more years were evaluated and stratified into four treatment groups: patients on R/S alone (n = 9), patients on R/S and stavudine/lamivudine (d4T/3TC) (n = 10), patients on R/S with or without d4T/3TC and statin (n = 11), or patients on R/S with or without d4T/3TC and fibrate (n = 5). All patients had suppressed levels of viral replication at all time points. T-cell responses were similar in all four groups before they were exposed to lipid-lowering agents. After the addition of lipid-lowering agents, absolute CD4 T-cell responses were lower in the statin group than in all other groups (p < .05), when measured after 6, 12, and 18 months of treatment. Conclusion: These data suggest that T-cell responses are influenced by the choice of anti-lipid agent and suggest that a prospective comparison is needed to determine the clinical relevance of these findings.",
keywords = "CD4 T-cell response, Fibrates, HMG-CoA reductase inhibitors, Hyperlipidemia",
author = "Shanil Narayan and Nanci Hawley and Pierre Gigu{\`e}re and Badley, {Andrew David}",
year = "2003",
month = "5",
doi = "10.1310/B05E-TFVN-UJ8L-MFHJ",
language = "English (US)",
volume = "4",
pages = "164--169",
journal = "HIV Clinical Trials",
issn = "1528-4336",
publisher = "Thomas Land Publishers Inc.",
number = "3",

}

TY - JOUR

T1 - Attenuated T-lymphocyte response to HIV therapy in individuals receiving HMG-CoA reductase inhibitors

AU - Narayan, Shanil

AU - Hawley, Nanci

AU - Giguère, Pierre

AU - Badley, Andrew David

PY - 2003/5

Y1 - 2003/5

N2 - Purpose: The protease inhibitor class of antiretroviral agents is associated with the unwanted side effect of hypertriglyceridemia, which is usually treated with either HMG-CoA reductase inhibitors (statins) or fibrates. However, since statin therapy is intrinsically immunomodulatory, we questioned whether the T-cell response of patients who received PI-based therapy plus statin differed from the response of patients on PI therapy alone or on PI therapy with a fibrate. Method: Retrospective cohort study. Results: Thirty-five patients who had received ritonavir/saquinavir (R/S)-based antiretroviral therapy for 5 or more years were evaluated and stratified into four treatment groups: patients on R/S alone (n = 9), patients on R/S and stavudine/lamivudine (d4T/3TC) (n = 10), patients on R/S with or without d4T/3TC and statin (n = 11), or patients on R/S with or without d4T/3TC and fibrate (n = 5). All patients had suppressed levels of viral replication at all time points. T-cell responses were similar in all four groups before they were exposed to lipid-lowering agents. After the addition of lipid-lowering agents, absolute CD4 T-cell responses were lower in the statin group than in all other groups (p < .05), when measured after 6, 12, and 18 months of treatment. Conclusion: These data suggest that T-cell responses are influenced by the choice of anti-lipid agent and suggest that a prospective comparison is needed to determine the clinical relevance of these findings.

AB - Purpose: The protease inhibitor class of antiretroviral agents is associated with the unwanted side effect of hypertriglyceridemia, which is usually treated with either HMG-CoA reductase inhibitors (statins) or fibrates. However, since statin therapy is intrinsically immunomodulatory, we questioned whether the T-cell response of patients who received PI-based therapy plus statin differed from the response of patients on PI therapy alone or on PI therapy with a fibrate. Method: Retrospective cohort study. Results: Thirty-five patients who had received ritonavir/saquinavir (R/S)-based antiretroviral therapy for 5 or more years were evaluated and stratified into four treatment groups: patients on R/S alone (n = 9), patients on R/S and stavudine/lamivudine (d4T/3TC) (n = 10), patients on R/S with or without d4T/3TC and statin (n = 11), or patients on R/S with or without d4T/3TC and fibrate (n = 5). All patients had suppressed levels of viral replication at all time points. T-cell responses were similar in all four groups before they were exposed to lipid-lowering agents. After the addition of lipid-lowering agents, absolute CD4 T-cell responses were lower in the statin group than in all other groups (p < .05), when measured after 6, 12, and 18 months of treatment. Conclusion: These data suggest that T-cell responses are influenced by the choice of anti-lipid agent and suggest that a prospective comparison is needed to determine the clinical relevance of these findings.

KW - CD4 T-cell response

KW - Fibrates

KW - HMG-CoA reductase inhibitors

KW - Hyperlipidemia

UR - http://www.scopus.com/inward/record.url?scp=0038676897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038676897&partnerID=8YFLogxK

U2 - 10.1310/B05E-TFVN-UJ8L-MFHJ

DO - 10.1310/B05E-TFVN-UJ8L-MFHJ

M3 - Article

C2 - 12815556

AN - SCOPUS:0038676897

VL - 4

SP - 164

EP - 169

JO - HIV Clinical Trials

JF - HIV Clinical Trials

SN - 1528-4336

IS - 3

ER -